T he immunosuppressive drug 15-deoxyspergualin (DSG) 4 is currently being used in clinical trials to prolong graft survival and reverse graft rejection (1) . It is a synthetic derivative of spergualin, originally isolated from Bacillus laterosporus, and it differs from other immunosuppressive agents both structurally and mechanistically (2) . DSG has been shown to bind certain heat shock proteins (hsp), such as heat shock cognate protein (hsc)70 and hsp90, and to partially inhibit the nuclear transport of the transcription factor, NF-B (3) (4) (5) . It is not clear how these molecular events induce clinical immunosuppression although many genes involved in the immune response have NF-B binding sites in their promoters. DSG has been shown to have a variety of effects on immune responses including decreased Ab production, inhibition of IL-6 and TNF-␣ production, and inhibition of early T and B cell development (6 -8) .
Despite the fact that its mechanism of action remains unclear, some studies indicate that DSG is more effective than other agents at inducing immunosuppression. In one case report, DSG was shown to reverse acute graft-vs-host disease that was nonresponsive to cyclosporin A and methylprednisolone (MP) (9) . In animal studies, DSG was more effective than FK506 and cyclosporin A in prolonging xenograft survival (10, 11) . DSG has also been used in combination therapy with other agents to increase allograft survival time. Of particular interest, a study by Contreras et al. (12) demonstrated that when a short course of DSG therapy was given in combination with three doses of anti-CD3 immunotoxin and MP, renal allograft survival in Rhesus monkeys was maintained for up to 550 days. When DSG was excluded from the treatment regime, grafts were rejected by day 50. A consistent finding in animals receiving DSG was decreased detection of IFN-␥ and TNF-␣ in plasma as compared with animals that received anti-CD3-immunotoxin and MP alone, suggesting that DSG inhibits Th1 CD4 cells that produce these proinflammatory cytokines.
DSG has also been effective in decreasing the severity of autoimmune diseases (13) . Experimental autoimmune encephalomyelitis (EAE) is a prototypical animal model used to study Th1-mediated autoimmunity and is clinically similar to the human neurologic disease multiple sclerosis (14, 15) . Disease in genetically susceptible strains of rodents can be induced either by injection of myelin-derived proteins or by adoptive transfer of preactivated encephalitogenic CD4 T cells. Immunization of (B10.PL ϫ SJL/J)F 1 mice with the NH 2 -terminal acetylated myelin basic protein (MBP) peptide (Ac1-11) results in the development of a chronic course of disease characterized by paralytic episodes with intermittent partial remission.
In this study, we investigated the effect of DSG on the course of this Th1-mediated autoimmune disease using a chronic relapsing model of EAE. In agreement with earlier DSG studies in the rat (16, 17) , we found that treatment with DSG delayed the onset of clinical signs of EAE and decreased disease severity. Investigations conducted in vitro into the mechanism of DSG immunosuppression showed that activated, but not naive, T cells were inhibited by DSG. Our findings indicate that DSG inhibits CD4 T cells directly by blocking cell cycle progression and altering Th1 effector functions. Thus, at least one mechanism of DSG immunosuppression results from inhibiting the proliferation of Th1 effector cells.
Materials and Methods

Mice
B10.PL and SJL/J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The MBP-TCR transgenic (tg) mice express a TCR transgene specific for the acetylated NH 2 -terminal peptide of MBP bound to I-A u and were generated as previously described (18) . (B10.PL ϫ SJL/J)F 1 (H-2 uxs ) mice, as previously described (19) , and MBP-TCR tg mice were bred and maintained in our colony at Yale University School of Medicine (New Haven, CT). All mice were used between 5 and 8 wk of age. Animal experiments were performed according to the Yale Animal Care and Use Center and national guidelines.
EAE induction and DSG treatment
The MBP peptide Ac1-11 (Ac-ASQKRPSQRHG) was synthesized and HPLC-purified by the W. M. Keck Foundation Biotechnology Resource Laboratory at Yale University. Female (B10.PL ϫ SJL/J)F 1 mice were immunized with 75 g of MBP Ac1-11 emulsified in CFA containing 4 mg/ml heat-killed Mycobacterium tuberculosis H37Ra (Sigma-Aldrich, St. Louis, MO) s.c. in each internal flank. Pertussis toxin (200 ng; List Biological Laboratories, Campbell, CA) in PBS was injected i.v. at the time of immunization and again 48 h later. DSG (kindly provided by Bristol-Myers Squibb, Lawrenceville, NJ) was administered i.p. beginning 4 days following peptide challenge and was used at a dose of 3.75 mg/kg in PBS. Mice were treated with DSG daily for 5 days and then for another 5 days following 1 day without treatment. Individual animals were assessed daily for symptoms of EAE and were scored as described (see Fig. 1 ).
Cell cultures
CD4 T cells were purified from spleens of MBP-TCR tg mice. RBC were removed by water lysis, and B cells were depleted by two rounds of panning with goat-anti-mouse IgA, M, and G (Zymed Laboratories, South San Francisco, CA). CD8 and remaining MHC class II-positive cells were removed with mAb and complement (Pel-Freez Biologicals, Rogers, AR). mAb used were 3.155 (rat anti-mouse Lyt2) purchased from American Type Culture Collection (ATCC; Manassas, VA) and maintained in our laboratory, 2.4G2 (rat anti-mouse FcR) produced locally (20) , and Y3JP (mouse anti-mouse I-A), which has been described (21) . Splenic APC were obtained from non-tg littermates by depleting T cells using 3.155, GK1.5 (rat anti-mouse CD4; ATCC), YCD3-1 (rat-anti-mouse Thy1) (21) , and rabbit complement. APC were inactivated with mitomycin C (Sigma-Aldrich).
For cytokine analysis, 3 ϫ 10 5 CD4 T cells from MBP-TCR tg mice were cultured with an equal number of inactivated APC and 5 g/ml Ac1-11 in 48-well plates. Cells were cultured in the serum-free medium HL-1 (BioWhittaker, Walkersville, MD) supplemented with L-glutamine because polyamine oxidase activity present in FCS can result in the breakdown of DSG into a product that is nonspecifically toxic to cells (22) . In some experiments, CD4 T cells were stimulated with 5 g/ml plate-bound anti-CD3 (2C11; ATCC), 1 g/ml soluble anti-CD28 (BD PharMingen, San Diego, CA) and 10% human rIL-2 (Hemagen, Columbia, MD). Preliminary proliferation assays were set up to determine the optimal dose of DSG to use in the in vitro studies (data not shown). As reported previously, we found that DSG inhibited proliferation of Ag-specific CD4 T cells in a dose-dependent manner (23) . In all subsequent experiments, DSG was used at a concentration of either 5 or 10 g/ml, doses that are believed to reflect levels achieved during in vivo treatment (24) . DSG was added at the beginning of the culture or 48 h later. Where indicated, supernatants were collected from the primary culture following 24 h of stimulation. Otherwise, cultures were maintained for 5 days, collected, washed, rested for 24 h, and restimulated with an equal number of APC and Ac1-11 or with 5 g/ml anti-CD3 and 1 g/ml anti-CD28. Supernatants were collected at 24 h and cytokine levels were measured by ELISA (BD PharMingen).
For proliferation assays, 1 ϫ 10 5 MBP-specific CD4 T cells were stimulated with an equal number of inactivated splenic APC and Ac1-11. DSG was added on day 0 or day 2 of culture. Cells were pulsed with 1 Ci of [ 3 H]TdR at the times indicated and were harvested 16 h later. Alternatively, freshly isolated CD4 T cells were incubated with 0.5 M CFSE (Molecular Probes, Eugene, OR) for 10 min at 37 o C and washed with PBS before culture. Proliferation was assessed by measuring mean fluorescence intensity using flow cytometry. In some cases, cells were incubated with PE-labeled annexin V (BD PharMingen) before FACS analysis to assess cell death.
In all experiments, data shown are representative of at least three experiments.
Cell surface staining and FACS analysis
FITC-conjugated anti-IL-2R␣ and anti-CD69 were purchased from BD PharMingen. Samples were analyzed on a FACSCalibur (BD Biosciences, Mountain View, CA) using CellQuest software.
Cell cycle analysis
MBP-specific CD4 T cells (3 ϫ 10 5 ) were cultured with an equal number of inactivated APC and Ac1-11 in 48-well plates. DSG was added to cultures on day 2. Cells were harvested on day 4 and dead cells were removed by density gradient centrifugation. Tissue culture supernatants were sterilefiltered to remove any remaining cells or debris. Live cells were replated at 3 ϫ 10 5 cells/ml in their original supernatants to preserve any autocrine growth factors produced. For cell cycle analysis, cells were incubated with propidium iodide (PI)/citrate mix (50 g/ml PI, 0.1% sodium citrate, 0.3% Nonidet P-40, 50 g/ml RNase A) and analyzed by flow cytometry.
Results
Treatment of mice with DSG delays the onset and reduces the severity of EAE
To determine whether treatment with DSG could alter the onset or severity of EAE in mice, we actively immunized (B10.PL ϫ SJL/ J)F 1 mice with the MBP peptide Ac1-11 emulsified in CFA and administered DSG i.p. testing a variety of treatment courses. We found that initiation of DSG treatment 2 days before immunization challenge and continued for a total of 5 days did not alter the onset or severity of EAE, even though a dose of 7.5 mg/kg DSG was administered. However, if DSG was administered for a total of 10 -14 days, the onset of EAE was delayed (data not shown). DSG also suppressed the EAE disease course when it was given at a lower dose (3.75 mg/kg), and when treatment for 10 days was initiated 4 days following immunization (Fig. 1 ). As shown in Fig.  1, 3 .75 mg/kg DSG treatment resulted in a substantial delay in the earliest onset of EAE from days 13 to 21. Individual animals were assessed daily for the severity of disease and mice treated with DSG had a less severe disease course (Fig. 1 ). This milder disease course was also not accompanied by signs of general malaise such as rough hair coat or weight loss that were commonly seen in PBS-treated mice. FIGURE 1. DSG delays the onset of EAE and decreases the severity of relapse. (B10.PL ϫ SJL/J)F 1 mice were immunized with Ac1-11 to induce EAE as described in Materials and Methods. Eighteen mice were treated with PBS (E) and 16 mice were treated with DSG (F) for 10 days beginning 4 days after Ag challenge in groups of three to five mice. Individual mice were scored daily for 55 days for severity of EAE using the following scale: 0, no disease; 1, limp tail or mild head tilt; 2, hind limb paresis or moderate head tilt; 3, front limb or hind limb paralysis; 4, front and hind limb paralysis; and 5, death. The daily scores were averaged from all mice in each group. Table I is a comparison of disease parameters of the two groups of mice studied. The disease parameters in the two groups of mice were quite different, as indicated by a substantial delay in the average onset of disease from day 18 in PBS-treated animals to day 31 when mice received DSG. This difference was found to be highly statistically significant ( p Ͻ 0.0001). In addition, the administration of DSG slightly reduced the incidence of EAE from 100 to 84%. Although DSG delayed the onset and reduced the incidence of EAE, those mice that succumbed to EAE did not have an altered early disease course compared with PBStreated mice. This is illustrated by a similar maximal disease score recorded for the first disease episode in the two groups of mice ( Fig. 1 ). In addition, an unaltered early disease course is indicated by similar average peak disease scores of 3.5 in PBS-treated mice and 2.7 in DSG-treated mice (Table I) .
Summarized in
Even though early disease symptoms were similar in the two groups, the overall severity of the disease course was reduced in the DSG-treated group. This is shown by a statistically significant reduction in the average daily disease score of DSG-treated mice compared with PBS-treated (1.3 vs 2.1, respectively) ( p ϭ 0.015) ( Table I ). In addition, the average disease score 35 days following onset was reduced from a disease score of 1.8 in the PBS group to 0.9 in the DSG group (Fig. 1) . A reduction in disease severity was most clearly demonstrated by the absence of mortality in DSGtreated mice, while mortality approached 28% in untreated mice (Table I ). These results indicate that while the immunosuppressive drug DSG was not able to inhibit the onset of the disease EAE in mice, it did have a beneficial affect in dampening the long-term severity of the disease. These data suggest that DSG does not prevent the priming of Th1 effector cells, but rather alters their functional capacity.
DSG does not inhibit activation of naive MBP-specific CD4 T cells
Because the onset of EAE was delayed rather than inhibited in DSG-treated mice, indicating that DSG did not prevent T cell priming, we examined whether DSG had any effects on the priming and activation of naive T cells in vitro. To test this, CD4 T cells were isolated from MBP TCR tg mice and activated in vitro with Ac1-11 in the presence and absence of DSG. In the MBP-TCR tg mouse, 95% percent of the CD4 T cells expressed the transgenic TCR ␤-chain, V␤8.2, of which only 1.2-1.5% are of the memory phenotype (21) . Thus, any response observed upon T cell activation should not have a substantial contribution from memory Ac1-11-specific T cells. T cell activation was determined by measuring the increased expression of two early activation markers, the ␣-chain of the IL-2R (IL-2R␣, CD25) and CD69, on the cell surface. As shown in Fig. 2A , the increased expression of both CD25 and CD69 was similar in DSG-treated and untreated cells harvested at 24 h following activation as demonstrated by similar percentages of cells staining positive and by similar mean channel fluorescence intensities for the positive-staining cells in the two groups. In addition, expression levels of CD25 remained similar after 72 h of culture in the two groups (Fig. 2B) . Expression of CD69 was consistently slightly higher (maximum 2-fold) on DSGtreated cells than on control cells on day 4 (Fig. 2B) . Treatment with DSG also did not alter the expression pattern of CD44 (data not shown).
We also assessed early activation of the naive T cells by measuring IL-2 production. After 24 h, no difference was detected in the level of IL-2 produced by T cells activated in the presence or absence of DSG (Fig. 2C) . The absence of demonstrable effects of DSG on expression of early activation markers or on production of IL-2 indicated that DSG did not inhibit the ability of naive CD4 T cells to recognize or respond to Ag presented by APC. These data support the observation that pretreatment of mice with DSG before FIGURE 2. DSG does not inhibit early activation events of naive CD4 T cells. MBP-specific splenic CD4 T cells were stimulated in vitro with inactivated splenic APC and Ac1-11. DSG was added to the indicated cultures on day 0. Cells were isolated at 24 (A) or 72 h (B), stained for CD25 (top graphs) or CD69 (bottom graphs), and analyzed by flow cytometry. The analysis gate was set on CD4 ϩ cells. Numbers to the right of the negative marker are the percent positive cells and numbers in parenthesis indicate the mean channel fluorescent intensity of the positive-staining cells. C, Supernatants were collected from cells stimulated in the absence (f) or presence (p) of DSG after 24 h of culture and IL-2 was measured by ELISA. 
DSG treatment of naive MBP-specific CD4 T cells results in decreased proliferation
Although DSG did not prevent the activation of naive CD4 T cells, the drug may affect downstream activation events such as cell proliferation and cytokine production. To examine this possibility, we measured the level of cell proliferation in the presence and absence of DSG following activation of naive CD4 T cells from MBP TCR tg mice. Initial studies demonstrated that cell proliferation as measured by [ 3 H]TdR incorporation was similar in DSG-treated and untreated cells stimulated with Ag after 48 h (Fig. 3A) . However, when proliferation was examined at 72 and 96 h, the control group had a time-dependent increase in cell proliferation while the DSGtreated T cells proliferated at the same level as that observed after 48 h (Fig. 3A) . To examine the extent of cell proliferation in more detail, proliferation was also measured by labeling the CD4 MBP TCR T cells with CFSE before stimulation. CFSE is an aminereactive dye that is incorporated into cells and divided equally between daughter cells during proliferation. The number of cell divisions can be determined using flow cytometry to measure the mean fluorescence intensity. As shown in Fig. 3B , only a small percentage of CD4 T cells had undergone cell division after 48 h of stimulation in either group. However, by 72 h, there was a detectable block in proliferation of DSG-treated cells relative to control cells, with the DSG-treated cells having undergone one less cell division (Fig. 3B) . The block in cell division was even more dramatic after 96 h with the DSG-treated cells showing no additional cell divisions beyond 72 h. In contrast, the T cells in the untreated group continued to proliferate after 72 h, and the majority of the cells had undergone one to four more cell divisions than the DSG-treated T cells (Fig. 3B) . These data are consistent with the [
3 H]TdR incorporation data (Fig. 3A) , that showed little difference in proliferation between the DSG-treated and untreated T cells at 48 h. In addition, the lack of continued cell proliferation with DSG treatment is reflected in the absence of additional cell division after 72 h.
To determine whether the failure to undergo cell division after 72 h was due to enhanced cell death following DSG treatment, cells were incubated with PE-labeled annexin V before FACS analysis at each of the three time points. After 48 h, only a small fraction of cells bound annexin V in either group (Fig. 3C , left panel), indicating that DSG does not have overt toxicity. At 72 h, 37% of the untreated cells were undergoing cell death as compared with 54% of the treated cells (Fig. 3C, middle panel) . By 96 h, there was a distinct bimodal distribution in the control group with 54% of the cells binding annexin V (Fig. 3C, right panel) . In contrast, 75% of the cells treated with DSG for 96 h bound annexin V (Fig. 3C, right panel) . The data for the control group, shown in Fig. 3C , is consistent with reported kinetics of T cell apoptosis following activation (25) . DNA analysis of both control and DSGtreated cells showed DNA fragmentation with ladder formation characteristic of apoptosis at 96 h (data not shown). These results suggest that there is an increase in cell death in cells cultured with DSG. However, it is not clear whether enhanced cell death results directly from the actions of DSG or is indirectly due to a block in cell cycle progression.
DSG inhibits cell cycle progression of recently activated T cells
Our results indicated that the predominant effect of DSG was not on primary stimulation of naive CD4 T cells, but rather on sustained proliferation and/or survival of activated T cells. This is consistent with our earlier finding that DSG was equally effective at inhibiting the onset of EAE, whether treatment was initiated before or 4 days following Ac1-11 challenge. To determine whether DSG could suppress proliferation of T cells which had been recently activated, we measured [ 3 H]TdR incorporation by CD4 T cells that were Ag-stimulated for 2 days before the addition of DSG. Addition of DSG to cultures on day 2 inhibited proliferation of MBP-specific CD4 T cells by 70% when measured at 96 h (Fig. 4A) .
To better assess the effect of DSG on the cell proliferation of activated T cells, DSG was added 2 days following Ag stimulation and incubated for an additional 2 days. Dead cells were removed by density gradient centrifugation and live cells were then replated in the medium they had been growing in to preserve any autocrine growth factors. They were then allowed to continue to proliferate for an additional 3 days. Cells were harvested daily, counted using trypan blue to distinguish live and dead cells, and incubated with PI to label DNA for cell cycle analysis. As shown in Fig. 4B , the total number of control cells increased daily. By day 7, a significant portion of the control cells had died as indicated by trypan blue staining. In addition, the control cells increased in total cell number between days 6 and 7 indicating that the cells were still undergoing proliferation at the same time cell death increased. In comparison, DSG-treated cells did not increase in total cell number after day 4, but underwent cell death on day 6 and 7 in a similar manner as the control cells.
Although DSG appeared to inhibit the proliferation of activated CD4 T cells, PI staining demonstrated that there was little difference in the percentage of control (50%) and treated cells (52%) in S and G 2 before replating on day 4 ( Fig. 4C and Table II) . Moreover, a larger percentage of DSG-treated cells remained in S and G 2 on days 6 and 7 compared with control cells (Fig. 4C and Table  II ). These data indicate that the failure of cells to proliferate in the presence of DSG results from a block in cell cycle progression. They further suggest that treatment with DSG can block cell cycle progression without directly inducing cell death.
DSG inhibits the production of IFN-␥ by direct action on the CD4 T cell
We next sought to determine whether DSG could also block the differentiation of naive T cells into polarized effector cells in addition to blocking cell division and cell cycle progression. Previous studies have shown that DSG can inhibit the production of IFN-␥ both in vivo and in vitro (12, 26) . This finding could be due to a direct effect of DSG or result from the block in proliferation leading to fewer cytokine-secreting cells. To determine whether DSG could directly inhibit cytokine production, naive MBP-specific CD4 T cells were stimulated with APC and Ac1-11 in primary culture in the presence or absence of DSG. DSG was added to the primary cultures on days 0 or 2, and the cells were cultured for 5 days. The cells were then rested for 24 h and equivalent numbers of treated or untreated cells were restimulated with Ag. DSG was added to primary cultures on day 0 to assess the effect on cytokine production by naive cells or on day 2 to assess the effect on cytokine production by cells that have started to polarize to a Th1 phenotype (27) . Supernatants were collected following 24 h of restimulation in the secondary culture and were analyzed for the production of IFN-␥ and IL-2. To determine whether any observed block in cytokine production resulted from a direct action of DSG on the T cell, highly purified MBP-specific CD4 T cells were activated in parallel in an Ag-independent manner with anti-CD3, anti-CD28, and IL-2. For secondary culture, the cells were restimulated with anti-CD3 and anti-CD28 in the absence of IL-2.
CD4 T cells stimulated with APC and Ac1-11 in the absence of DSG produced high levels of IFN-␥ upon restimulation (Fig. 5A,  left panel) . In contrast, little or no IFN-␥ was produced by cells that had been treated with DSG on days 0 or 2 in the primary culture. Addition of IL-12 and anti-IL-4 to the primary culture induced higher levels of IFN-␥ production (208 Ϯ 11 ng/ml) by control cells upon restimulation (data not shown). In comparison, IFN-␥ production remained lower in similar cultures in which DSG was added on day 2 (47 Ϯ 10 ng/ml), indicating that IL-12 is not sufficient to overcome the inhibitory effects of DSG (data not shown).
Similar results were obtained when CD4 T cells were stimulated in an Ag-nonspecific manner with anti-CD3 and anti-CD28. The control cells produced high levels of IFN-␥ in secondary culture, and the addition of DSG to the primary culture either on day 0 or 2 inhibited IFN-␥ production by 80% (Fig. 5A, right panel) . The effect of DSG treatment on IL-2 production was much less dramatic. The addition of DSG to Ag-activated cells on day 0 of the primary culture resulted in only 50% inhibition in IL-2 production and treatment on day 2 inhibited production by only 27% (Fig. 5B,  left panel) . Furthermore, there was little difference in the level of IL-2 produced by control cells and cells treated with DSG on day 2 in the Ag-independent culture. In several experiments, the addition of DSG to the primary cultures on day 0 resulted in slightly higher levels of IL-2 production upon restimulation (Fig. 5B, right   FIGURE 4 . DSG blocks cell cycle progression in activated cells. A, CD4 T cells were stimulated as described for Fig. 4 and DSG was added to cultures on day 2. Proliferation was measured by adding [ 3 H]TdR at the times indicated and cells were harvested 16 h later. Graphs compare proliferation by control and DSG-treated cells. B, Day 2 DSG-treated and control CD4 T cells were stimulated with APC and Ac1-11 for 4 days, dead cells were removed, and live cells were replated at a concentration of 3 ϫ 10 5 cells/well. Cells were harvested daily and live (p) and dead (u) cell numbers from control and DSG-treated cultures were compared. Live and dead cells were distinguished using trypan blue. C, Cell cycle analysis of control and DSG-treated cells incubated with PI were compared by FACS analysis immediately following live cell recovery on day 4 (top histograms) and then 2 days (middle histograms) and 3 days (bottom histograms) after replating the cells. a CD4 T cells were Ag-stimulated for 4 days prior to secondary culture in medium alone or DSG (5 g/ml) for an additional 2-3 days. Cell cycle analysis was performed by staining cells with PI and analyzing on a flow cytometer.
b Percentage of cells in each area of the cell cycle as determined by flow cytometry. The values are from one of three separate analyses.
panel). Little IL-4 was detected in any of the cultures (data not shown) suggesting that the lack of IFN-␥ production in the DSGtreated groups is not due to an IL-4-induced skewing toward a Th2 response. These data suggest that the inhibition in IFN-␥ production observed following DSG treatment results from a direct action of DSG rather than from a decrease in the number of cells producing IFN-␥ in the cultures.
Discussion
The efficacy of DSG as a potent immunosuppressive agent has been well-established. However, its mechanism of action and primary target(s) on both the cellular and molecular levels remain unclear. In this study, we investigated the mechanism of action of DSG on CD4 T cell activation and in autoimmunity. Using the CD4 Th1 T cell-dependent autoimmune disease EAE, we were able to show that only a short-term treatment with DSG was needed to delay the onset of clinical signs of EAE, decrease the overall severity of the disease, and enhance survival. The DSG inhibitory effect we observed with a mouse model of EAE is consistent with previously published studies in the rat (16, 17, 28) . In addition, we were able to demonstrate that DSG does not alter primary T cell activation, but exerts a direct effect on recently activated T cells by halting cell cycle progression and inhibiting IFN-␥ production. The DSG-treated cells were able to undergo several rounds of cell division in the absence of overt apoptotic cell death suggesting that the delay in EAE onset that we observed was due to the slower accumulation of MBP-specific Th1 cells required for the induction of EAE. The overall severity of the EAE disease course in DSG-treated mice was significantly reduced as compared with control mice, suggesting that DSG was able to permanently alter the Ag-specific T cells themselves, perhaps by altering the level of cytokine production thought to be important in EAE pathogenesis.
It has been suggested that the acquisition of IFN-␥ production following activation of naive T cells is linked to cell cycle number, with a higher percentage of T cells producing IFN-␥ with increasing cell cycle numbers (29 -31) . Thus, the lack of IFN-␥ production (Fig. 5) we observed following DSG treatment could be directly related to the block in cell cycle progression observed by both CFSE (Fig. 3) and PI (Fig. 4) staining. However, it is also possible that the block in cell cycle progression and inhibition of IFN-␥ production we observed are independent events. In support of this are two recent studies that demonstrated that noncycling T cells have the capacity to produce IFN-␥, even when blocked in G 1 (32, 33) . In addition, the study by Ben-Sasson et al. (33) showed that the ability of a T cell to produce IFN-␥ was not regulated by the number of cell divisions alone. They further showed that naive CD4 T cells stimulated with peptide Ag for 2 days that had undergone 0, 1, or 2 cell divisions produced IFN-␥, with 43, 85, and 91% of the cells producing IFN-␥, respectively. Thus the inability of T cells treated with DSG to progress past two to three cell divisions would not necessarily lead to the profound inhibition of IFN-␥ production that we observed. Also it is known, using IFN-␥ Ϫ/Ϫ mice that EAE disease is more severe rather than less (34, 35) , as would be predicted. This could reflect the ability of IFN-␥ to kill proliferating T cells (36) .
Our results demonstrating that DSG inhibited production of IFN-␥ by direct action on CD4 T cells, without an apparent link to the block in cell cycle progression, indicates that DSG may target several different cellular processes. The only known targets of DSG are hsc70 and hsp90 (3, 4) . Because it was also shown that DSG partially inhibits NF-B transport into the nucleus, one model that has been proposed is that hsc70 acts as a chaperone for NF-B translocation and that by binding hsc70, DSG inhibits its nuclear transport (8) . However, hsp interact with a large number of proteins. hsp90-binding agents, such as the benzoquinoid ansamycins geldanamycin and herbimycin A, have been shown to inhibit a variety of protein tyrosine kinases (PTK) suggesting a role for hsp in maintaining signal transduction pathways (37, 38) . It is possible that DSG similarly inhibits PTK resulting in the immunosuppression observed in our study. PTKs are involved in transducing many intracellular signals including the activation of the mitogen-activated protein (MAP) kinase pathway (39) . Two MAP kinase kinases (MKK), MKK4 and MKK7, activate c-Jun NH 2 -terminal kinases (JNK1 and JNK2), and these molecules in turn influence Th differentiation and cytokine production (39 -41) . JNK2 has been reported to be critical for IFN-␥ production and for polarization of CD4 ϩ T cells to a Th1 phenotype (40, 41) . Thus, it is conceivable that the inhibition of IFN-␥ production that we observed in our studies could result from a block in JNK2 activity or the activity of an upstream protein kinase.
Although there are no reports describing a direct role for hsp in the activation of MKK4/7 or JNK, it has recently been demonstrated that hsp90 and hsp70 are detected in a multimolecular signaling complex which includes the recently described kinase suppressor of Ras (KSR) and the MAP kinase kinases, MEK1 and MEK2 (42) . Geldanamycin decreases the half-life of KSR, presumably by interfering with its association with hsp90 (42) . Both MEK1 and MEK2 have been implicated in maintaining cell cycle progression through G 1 , M, and G 2 (43, 44) . Thus, one can speculate that DSG may block cell cycle progression by interfering with the signaling complex formed between KSR and MEK1/2.
Odaka et al. (45) have recently reported that a DSG analog, methyldeoxyspergualin, induced apoptosis in rapidly dividing T cell hybridomas while slower growing hybridomas and naive splenic T cells were more resistant. They also found that mitochondrial transmembrane potential was reduced in cells treated with methyldeoxyspergualin, suggesting that the drug may induce apoptosis directly by interfering with mitochondrial respiratory function. In keeping with Odaka's findings, we found that DSG had no obvious effects on the survival of unstimulated MBP-specific CD4
ϩ T cells (data not shown), but that increased cell death accompanied the block in proliferation of naive CD4 T cells following activation. In contrast, when cells were stimulated for 2 days before treatment with DSG, cell cycle progression was effectively blocked without enhanced cell death. There are two possible explanations for these findings. First, DSG may directly induce death of CD4 T cells only at selective stages of their activation. Alternatively, the predominant effect of DSG may be a block in cell cycle progression that subsequently leads to cell death in some instances. Cells that have received prior activation may be sensitive to the DSG-induced block in cell cycle progression, but remain more resistant to cell death due to enhanced expression of survival factors upon stimulation.
Although it is clear that DSG strongly inhibits CD4 T cell function, short-term treatment with DSG alone was not sufficient to completely abrogate the onset of clinical signs of EAE. This is in contrast to the long-term inhibition in graft rejection observed when DSG was given in combination therapy to kidney graft recipients in a primate model of transplantation (12) . This may be due to the failure of Th2-mediated responses, which were observed in the transplantation study, to be induced in the EAE model used in this study. We speculate that although DSG does not drive polarization to Th2-type CD4 T cells, Th2 cells may be more resistant to the effects of DSG and maintain inhibition of Th1-mediated responses upon cessation of treatment. We have started to address this issue by comparing the effect of DSG on CD4 T cells from tg mice expressing a TCR specific for pigeon cytochrome C stimulated in vitro and polarized to a Th1-or Th2-type phenotype. In preliminary experiments, we have found that DSG inhibits cell cycle progression of both subsets of Th cells, but that cells polarized to a Th2 phenotype are somewhat less susceptible to cell death (our unpublished data). This is not surprising because IL-4 is known to be a survival factor, and appears to act in part by enhancing survival proteins such as Bcl-2 and Bcl-x L (46) . However, the presence of IL-4 alone does not appear to be sufficient for overcoming the effects of DSG, as addition of IL-4 to MBP-specific CD4 T cells enhanced survival only marginally (data not shown), suggesting that other, undefined, mechanisms are involved in the enhanced survival of Th2-type CD4 T cells.
Taken as a whole, our data suggest that the clinical immunosuppressive effects of DSG observed in both human and animal models is a direct affect of DSG on recently activated T cells. In addition, immunosuppression by DSG appears to occur at multiple levels, with cell cycle progression and cytokine production being affected. DSG very likely prevents the accumulation of autoreactive or alloreactive cells due to their inability to proliferate, leading to a less severe immune response. In addition, reduced IFN-␥ production may result in a dampened inflammatory response. Thus, immunosuppression with DSG seems well suited to those clinical situations when T cell suppression would be of most benefit.
